Table 2.
Summary statistics for atorvastatin and boceprevir pharmacokinetic parameters
| Drug | Parameter | Treatment | Geometric meana | Comparison | GMR | 90% CI for GMR |
|---|---|---|---|---|---|---|
| Atorvastatinb | Cmax (ng/ml) | Atorvastatin + boceprevir | 24.7 | Atorvastatin + boceprevir vs atorvastatin alone | 2.66 | 1.81–3.90 |
| Atorvastatin alone | 9.29 | |||||
| AUCinf (ng · h/ml) | Atorvastatin + boceprevir | 201 | Atorvastatin + boceprevir vs atorvastatin alone | 2.32 | 1.85–2.90 | |
| Atorvastatin alone | 86.8 | |||||
| Boceprevirc | Cmax (ng/ml) | Boceprevir + atorvastatin | 1,969 | Boceprevir + atorvastatin vs boceprevir alone | 1.04 | 0.888–1.21 |
| Atorvastatin alone | 1,900 | |||||
| AUC0–8 (ng · h/ml) | Boceprevir + atorvastatin | 6,995 | Boceprevir + atorvastatin vs boceprevir alone | 0.960 | 0.903–1.02 | |
| Atorvastatin alone | 7,290 |
a
Model-based (least-squares) geometric mean: based on mixed-effect model extracting the effect due to treatment as the fixed effect and subject as the random effect. Ten subjects were included in the study.
b
Single-dose atorvastatin with and without multiple-dose boceprevir.
c
Multiple-dose boceprevir with and without single-dose atorvastatin.